Papers
-
Miyazaki T, Nakajima W, Hatano M, Shibata Y, Kuroki Y, Arisawa T, et al. Visualization of AMPA receptors in living human brain with positron emission tomography. Nat Med 2020;26:281–8. https://doi.org/10.1038/s41591-019-0723-9.
-
Hatano M, Miyazaki T, Ishiwata Y, Nakajima W, Arisawa T, Kuroki Y, et al. Biodistribution and radiation dosimetry of the positron emission tomography probe for AMPA receptor, [11C]K-2, in healthy human subjects. Sci Rep 2021;11.
https://doi.org/10.1038/s41598-021-81002-3. -
Arisawa T, Miyazaki T, Ota W, Sano A, Suyama K, Takada Y, et al. [11C]K-2 image with positron emission tomography represents cell surface AMPA receptors. Neurosci Res 2021;173:106–13. https://doi.org/10.1016/j.neures.2021.05.009.
Clinical Trial
Many clinical trials involving AMPA-PET have been performed, including physician-initiated clinical trials of automatic PET drug synthesizers. This is a list of tests that have been or are being conducted. The test details are linked to the test number (separate site).
| Study Title | Study No. | Subject | Number of cases | Period |
|---|---|---|---|---|
| Clinical trial to evaluate the efficacy and safety of [11C]K-2 in healthy volunteers | UMIN000020975 | Healthy | 8 | 2016/02/10 – end |
| The clinical trial to evaluate the efficacy of [11C]K-2 in refractory epilepsy patients undergoing anterior temporal lobectomy | UMIN000025090 | Refractory epilepsy | 8 | 2016/11/30 – |
| The clinical pilot study to examine the distribution of [11C]K-2 in depression, bipolar disease, schizophrenia, addiction,ASD,epilepsy and FTD patients in oreder to develope the novel diagnostic method in cross-sectional way toward these diseases | UMIN000025132 | Mental ilness and healthy | 110 | 2016/12/2 – |
| Clinical trial to examine the effective dose and the safety of [11C]K-2 synthesized by dedicated machine in healthy male volunteers | UMIN000026357 | Healthy | 12 | 2017/3/6 – end |
| The exploratory clinical trial to evaluate the efficacy of [11C]K-2 in stroke patients under rehabilitation. | UMIN000029952 | Sequelae of cerebral infarction | 20 | 2017/11/13 – |
| The clinical trial to examine the densities of AMPA receptors in epilepsy patients with [11C]K-2 | UMIN000031624 | Epilepsy | 35 | 2018/4/1 – |
| Clinical trial to examine the effectiveness of AMPA-PET to identify epileptogenic focus in refractory epilepsy patients | JapicCTI-194576 | Refractory epilepsy | 40 | 2019/1/16 – |
| Investigator-initiated clinical trial to evaluate the efficacy of AMPA-PET in functional recovery process by rehabilitation for subjects registered in the clinical phase II trial of T-817MA (T817MAJP201R trial) | JapicCTI-194711 | Stroke | 10 | 2019/04/15 – |
| The relationship of AMPA receptor density with presence or absence of subsequent onset in high-risk cases of psychosis: A longitudinal PET study using [11C] K-2 | jRCTs031190151 | ARMS | 30 | 2019/12/2 – |
| The relationship of AMPA receptor density in patients with autism spectrum disorder: A transversal PET study using [11C] K-2 | jRCTs031190149 | ASD | 30 | 2019/12/2 – |
| The relationship of AMPA receptor density in patients with depression and bipolar disorder :a transversal PET study using [11C]K-2 | jRCTs031190150 | Depression, Bipolar disorder | 60 | 2019/12/2 – |
| The relationship of AMPA receptor density in patients with schizophrenia: A transversal PET study using [11C] K-2 | jRCTs031190197 | Schizophrenia | 30 | 2020/1/31 – |
| A pilot study to validate the estimate accuracy between standard uptake value ratio and non displaceable binding potential obtained from [11C]K-2 PET imaging in major cognitive disorders. | jRCTs031190262 | Dementia | 92 | 2020/4/2 – |
| A transversal PET study using [11C]K-2 to investigate age-and-sex-related changes AMPA receptor density in healthy volunteers. | jRCTs031200083 | Healthy | 100 | 2020/8/12 – |